Masked T-cell engagers: cancer immunotherapies for the future?

By Sheena Cruickshank, Professor in Immunology, University of Manchester
Jonathan Worboys, Research Fellow, Institute of Immunology and Inflammation, Manchester University

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own immune arsenal to fight cancer.

In the trial, which is still in progress and has not yet undergone peer-review, patients with advanced prostate cancer who had failed to respond to other treatments were given VIR-5500. Remarkably, initial findings showed that in the patients who received the highest doses,…

Read complete article

~	A concerto played with trash: Barbican offers a masterclass in thought-provoking classical programming

~	Indigenous-led renewable energy projects offer benefits that reach far beyond reducing carbon emissions

~	When war looks like prophecy: How U.S. ‘end time’ narratives frame the war with Iran

~	Human vision: what we actually see – and don’t see – tells us a lot about consciousness

~	The UK’s high electricity prices are here to stay. But could they offer an opportunity?

~	How moss could help roads cope with heavy rain and reduce air pollution

~	If you think your toddler’s often ill, you’re right – what going to nursery means for catching colds and building immunity

~	Trying your best in a second language? Here’s why native speakers seem so rude

~	How hatred of Jews became a common ground for Islamic terrorists and left-wing extremists, fueling domestic terrorism

~	Taking Churchill off the banknote isn’t ‘erasing history’ – but it is a matter of identity